Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 9
Summary
- Conditions
- Advanced Solid Tumours
- Cervical Cancer
- Lymphoma
- Malignant Mesothelioma
- Non -Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Phase ?a: open, multi-dose, dose escalation. Phase ?b: open, fixed-dose, cohort expansion.
Phase ?a: open, multi-dose, dose escalation. Phase ?b: open, fixed-dose, cohort expansion.
Tracking Information
- NCT #
- NCT03852823
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jin Li, PhD Shanghai East Hospital Principal Investigator: Lingying Wu, PhD Cancer Institute and Hospital, Chinese Academy of Medical Sciences Principal Investigator: Caicun Zhou, PhD Shanghai Pulmonary Hospital, Shanghai, China